Text Size

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study

Hori Y, Oka K, Inai M.


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Toho University Omori Medical Center, Toho University Graduate School of Medicine, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan; Global Clinical Development and Operations, Product Development Division, Clinical Operations Japan/Asia, Santen Pharmaceutical Co., Ltd., Kita-ku, Ofukacho Osaka, Japan

Related Publications

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.


Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022